2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - Great Hall AD
Technology and Procedures, Molecular Testing, Treatment Considerations, Drug Development, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Adverse Events, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, MDS, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult
PAPER

720 Comparable outcomes following haploidentical, MSD, and MUD HCT in adult AML patients with pre-transplant detectable MRD using PTCy-based GVHD prophylaxis: A study from the ALWP of the EBMT

Yishan Ye, MD, Maud Ngoya2, Maija Itälä-Remes3, Jan Vydra, MD, PhD4, Raynier Devillier, PhD5, Jaime Sanz, MD, PhD6, Mi Kwon, MD,PhD7, Linde Morsink8, Peter Von Dem Borne, MD, PhD9, Jurjen Versluis Sr, MD, PhD10, Francis Ayuketang Ayuk, MD11, Simona Sica, MD, PhD12, Ibrahim Yakoub-Agha, MD, PhD13, Alexander Kulagin14, Montserrat Rovira15, Gesine Bug, MD16, Ali Bazarbachi, MD, PhD17, Giorgia Battipaglia18, Simona Piemontese, MD19, Annalisa Ruggeri, MD20, Lin Li21, Yi Luo22, Jimin Shi23, Yanmin Zhao24, Arnon Nagler I, MD25, Mohamad Mohty, MD, PhD26, He Huang, MD, PhD27, Fabio Ciceri, MD28, Eolia Brissot, MD, PhD29
1 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
2 European Society for Blood and Marrow Transplantation, Paris Study Unit, Paris, France
3 Turku University Hospital, Turku, Finland
4 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
5 Institute Paoli-Calmettes, Marseille, France
6 Hospital Universitari i Politècnic La Fe, Valencia, Spain, Universitat de Valencia, Valencia, Spain
7 Hospital General Universitario Gregorio Marañón, Madrid, Spain
8 University Medical Center Groningen, Groningen, Netherlands
9 Leiden University Medical Center, Leiden, Netherlands
10 Erasmus MC Cancer Institute, Rotterdam, Netherlands
11 University Hospital Eppendorf, Hamburg, Germany
12 Universita Cattolica del Sacro Cuore, Rome, Italy
13 CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000, Lille, France
14 RM Gorbacheva Research Institute, Pavlov University, St. Petersburg, Russian Federation
15 Hospital Clínic of Barcelona, Barcelona, Spain
16 University Hospital - Goethe University Frankfurt, Frankfurt Main, Germany
17 American University of Beirut, Beirut, Lebanon
18 Federico II University of Naples, Naples, Italy
19 IRCCS San Raffaele Institute, Milano, Italy
20 IRCCS San Raffaele Institute, Milano, Italy
21 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
22 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
23 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
24 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
25 Chaim Sheba Medical Center, Tel Hashomer, Israel
26 Saint-Antoine Hospital Sorbonne University, Paris, France
27 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
28 IRCCS San Raffaele Institute, Milano, Italy
29 Saint-Antoine Hospital Sorbonne University, Paris, France

Background

Disease relapse remains a major challenge after allogeneic hematopoietic cell transplantation (allo-HCT) for acute myeloid leukemia (AML), particularly in patients with detectable measurable residual disease (MRD) at the time of transplant. Given that haploidentical (HAPLO) grafts may be associated with a stronger graft-versus-leukemia effect but higher incidence of graft-versus-host disease (GVHD) than HLA-matched donor grafts, and that post-transplant cyclophosphamide (PTCy) is now standard for HAPLO grafts and increasingly used in HLA-matched settings, we compared outcomes of PTCy-based HAPLO, matched sibling (MSD) or fully matched unrelated donors (MUD) in AML patients transplanted in complete remission (CR) and with detectable MRD  .

Methods

Data from 1251 adult AML patients receiving a first allo-HCT in first or second CR (CR1/CR2) from 202 EBMT centers between 2010 and 2024 were analyzed. 1005 patients were transplanted in CR1 and 246 in CR2. All had detectable MRD at transplant. Grafts from an HLA-mismatched unrelated donor (<10/10), umbilical cord blood, or grafts with ex-vivo manipulation were excluded. All patients were transplanted with PTCy-based GVHD prophylaxis. Multivariable Cox regression models were used to evaluate the impact of donor type on outcomes.

Results

A total of 1251 HCTs were analyzed, comprising 825 (66%) HAPLO, 147 (12%) MSD, and 279 (22%) MUD transplants. The median age of the entire study population was 56 years (range: 18–75). Baseline characteristics were well-balanced across the three cohorts, with no statistically significant differences observed in European LeukemiaNet risk classification, disease status at transplant (CR1 vs. CR2), Karnofsky performance status score (<90 vs. ≥90), or between myeloablative conditioning (MAC) vs. reduced intensity conditioning (RIC) regimens.

The 2-year probabilities of overall survival (OS) and progression-free survival was 65.5% (95% CI: 62.5–68.4) and 59.3% (95% CI: 56.2–62.2) for the entire cohort, respectively. On multivariable analysis, no significant differences were observed between the three cohorts in PFS and overall survival OS. Compared with the HAPLO-HCT group (reference), MSD-HCT was associated with a significantly lower incidence of 100-day grade III-IV acute GVHD (aGVHD) (hazard ratio [HR]=0.42, 95% CI: 0.18–0.97; p=0.04) and 2-year non-relapse mortality (NRM) (HR=0.46, 95% CI: 0.22–0.95; p=0.04). A 10/10 MUD-HCT was also associated with a significantly lower incidence of 100-day grade II-IV aGVHD (HR=0.67, 95% CI: 0.46–0.98; p=0.04). The 2-year relapse incidence (RI) for the HAPLO, MSD, and MUD cohorts was 25.7%, 28.4%, and 29.7%, respectively, with no statistically significant differences between the groups.

Independent of donor type, female-to-male HCTs were associated with a higher 2-year incidence of extensive chronic GVHD (cGVHD) (HR=3.24, 95% CI: 1.47–7.18; p=0.004). Compared with MAC, RIC was associated with a higher 2-year cumulative RI (HR=1.44, 95% CI: 1.04–1.98; p=0.03), worse PFS (HR=1.36, 95% CI: 1.06–1.75; p=0.02), and worse OS (HR=1.41, 95% CI: 1.08–1.83; p=0.01). Furthermore, the use of peripheral blood as the graft source was associated with a higher incidence of 2-year cGVHD of all grades (HR=1.56, 95% CI: 1.04–2.33; p=0.03).

Conclusions

For AML patients transplanted in CR with detectable MRD using PTCy-based GVHD prophylaxis, HAPLO, MSD, and MUD allo-HCTs achieved comparable survival outcomes.

Yishan Ye, MD: No relevant conflicts of interest to declare.